Bristol Myers Squibb (BMY) CEO Giovanni Caforio on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 07/28/21
Bristol Myers Q2 Earnings Slightly Ahead Of Estimates, Trims FY21 GAAP EPS GuidanceBenzinga • 07/28/21
Bristol Myers swings to profit to beat second-quarter estimates as Opdivo returns to growthMarket Watch • 07/28/21
Bristol Myers Squibb (BMY) Stock Moves -0.19%: What You Should KnowZacks Investment Research • 07/16/21
Bristol Myers says late-stage trial of head and neck cancer treatment failed to meet main goalsMarket Watch • 07/16/21
Bristol Myers Squibb Provides Update on CheckMate -651 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus EXTREME Regimen as First-Line Treatment for Squamous Cell Carcinoma of the Head and NeckBusiness Wire • 07/16/21
Dividend Harvesting: Week 19 Update, $1,900 Invested, 39 Positions, $122.02 In Annual DividendsSeeking Alpha • 07/14/21